Study finds that for each 10% increase of certain bacteria type in the gut microbiome, the risk of hospitalisation for infections falls by up to a quarter

(Press-News.org) **Note: the release below is a special early release from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024, Barcelona, Spain, 27-30 April). Please credit the congress if you use this story**

A study of two large European patient cohorts has found that for every 10% increase in butyrate-producing bacteria in a patient’s gut, the risk of hospitalisation for any infection falls by between 14 and 25% across two large national cohorts. The study will be presented at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) in Barcelona, Spain (27-30 April) and is by Robert Kullberg, Amsterdam University Medical Center, The Netherlands, and colleagues.

Microbiota alterations are common in patients hospitalised for severe infections and preclinical models have shown that anaerobic butyrate-producing gut bacteria protect against systemic infections. These bacteria were investigated because they are commonly depleted in patients hospitalised for severe infections. Second, butyrate may have protective effects in several intestinal diseases (other than infections).

However, the relationship between microbiota disruptions and increased susceptibility to severe infections in humans remains unclear. In this study, the authors investigated the relationship between baseline gut microbiota and the risk of future infection-related hospitalisation in two large population-based cohorts - from the Netherlands (derivation; HELIUS) and Finland (validation; FINRISK 2002).

Gut microbiota were characterised by sequencing the DNA of bacteria to identify the different types of bacteria present in faecal samples of the participants. The authors measured microbiota composition, diversity, and relative abundance of butyrate-producing bacteria. The primary outcome was hospitalisation or mortality due to any infectious disease during 5–7-year follow-up after faecal sample collection, based on national registry data. The authors then examined associations between microbiota and infection-risk using computer modelling. Further statistical  modelling was used to adjust for variables including demographics, lifestyle, antibiotic exposure, and comorbidities.

The researchers profiled gut microbiota from 10699 participants (4248 from The Netherlands and 6451 from Finland. A total of 602 participants (The Netherlands: n=152; Finland: n=450) were hospitalised or died due to infections (mainly community-acquired pneumonia) during follow-up.

Gut microbiota composition of these hospitalised/deceased participants differed from those without hospitalisation for infections. Specifically, each 10% higher abundance of butyrate-producing bacteria was associated with a reduced risk of hospitalisation for infections – 25% lower for participants from the Dutch cohort and 14% lower for the Finnish cohort. All types of infections were assessed together, not any one in particular. These associations remained unchanged following adjustment for demographics, lifestyle, antibiotic exposure, and comorbidities.

The authors say: “Gut microbiome composition, specifically colonisation with butyrate-producing bacteria, is associated with protection against hospitalisation for infectious diseases in the general population across two independent European cohorts. Further studies should investigate whether modulation of the microbiome can reduce the risk of severe infections.”

The authors say further analysis will be needed before trails in patients can begin. One of the challenges is the face are the butyrate-producing bacteria are strictly anaerobic (meaning they respire without using oxygen and cannot tolerate oxygen), which makes it very difficult to transport viable bacteria into the gut. Several research groups are working on addressing these challenges.

Robert Kullberg, Amsterdam University Medical Center, Amsterdam, The Netherlands T) +3120 566 2929 E) r.f.j.kullberg@amsterdamumc.nl

Tony Kirby in the ECCMID Media Centre T) +44 7834 385827 E) tony@tonykirby.com

This press release is based on abstract CS0502 at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The material has been peer reviewed by the congress selection committee. It is about to be submitted to a medical journal for publication. The full paper is not yet available but the authors are happy to answer your questions.

For full abstract click here

 

END